aluates Reports

$ 0.0

Automative

Global Pharmaceutical Biomanufacturing Market Research Report 2025

Published Date: December 2025

Report Code: QYRE-Auto-26E19785

BUY CHAPTERS

Global Pharmaceutical Biomanufacturing Market Research Report 2025

Code: QYRE-Auto-26E19785

Report

December 2025

Pages:134

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Pharmaceutical Biomanufacturing Market Size

The global market for Pharmaceutical Biomanufacturing was valued at US$ 518560 million in the year 2024 and is projected to reach a revised size of US$ 951994 million by 2031, growing at a CAGR of 9.4% during the forecast period.

Pharmaceutical Biomanufacturing Market

In the pharmaceutical field, biomanufacturing refers to the use of living biological systems (such as mammalian, microbial, or plant cells) as "production factories" to transform complex biomolecules into drugs for the treatment or prevention of diseases through precisely controlled cultivation, fermentation, separation, and purification processes. This process differs from traditional chemical synthesis in that it emphasizes the correct folding, modification, and biological activity of macromolecules such as proteins and nucleic acids. It also requires strict adherence to regulatory standards such as cGMP to ensure product safety, efficacy, and batch consistency. Typical products include monoclonal antibodies, recombinant proteins, vaccines, and gene or cell therapy formulations, reflecting the shift in modern pharmaceutical manufacturing from chemical manufacturing to bio-driven innovation.

The upstream biomanufacturing process in pharmaceuticals encompasses key supply chains such as equipment, reagents, and raw and excipient materials, forming the foundation of the entire industry chain. Equipment includes cell separation and elutriation machines, flow cytometers, cell culture incubators, biosafety cabinets, reactors (such as Wave, G-Rex, and CliniMACS Prodigy), nucleic acid synthesizers, HPLC separation systems, and fermenters. These equipment are widely used in the production of CAR-T, small nucleic acids, mRNA, monoclonal antibodies, and vaccines. Raw materials include DNA plasmids, enzymes, lipid nanoparticles, culture media, cell lines (such as CHO), cytokines, and chromatography media. The upstream industry landscape is still dominated by multinational giants such as GE Healthcare, Lonza, Miltenyi, Thermo Fisher, Cytiva, and Sartorius. Domestic companies such as LePure Biopharmaceuticals, Novozymes, GenScript, Nanovitamin Biotech, Lanxiao Technology, Dongfulong, and Chutian Technology are gradually replacing imports, particularly with breakthroughs in separation and purification media, as well as certain reagents and equipment. However, overall, gaps remain in high-end instruments and core consumables. Overall, the upstream industry demonstrates a pattern of "high technological barriers for multinational companies and rapid catching-up for local companies."

The midstream sector primarily focuses on the R&D and production of biopharmaceuticals, including antibody drugs, CAR-T therapies, mRNA vaccines, small nucleic acid drugs, recombinant proteins, and blood products. This sector encompasses both large pharmaceutical companies and CDMO/CMO service providers. Globally, multinational pharmaceutical companies such as Roche, Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb still dominate high-end innovation in the industry. In China, leading domestic companies such as WuXi AppTec, Corning Life Sciences, GenScript, Asymchem, Zhifei Biopharmaceuticals, Sinovac Biotech, and Kangtai Biologics are experiencing rapid growth, with some achieving international breakthroughs in vaccines, CDMOs, and antibody drugs. Geographically, North America and Europe are centers of innovation and R&D, while the Asia-Pacific region, particularly China, has gradually become a global hub for biomanufacturing production, creating a "European and American innovation, Asia-Pacific manufacturing" landscape. The midstream sector is currently transitioning towards digital factories, continuous flow production, and modularized capacity layouts, giving Chinese companies greater opportunities to directly adopt next-generation process standards when building new production capacity.

The downstream biomanufacturing sector in the pharmaceutical industry primarily serves healthcare providers and patients. Typical users include large tertiary hospitals, specialized oncology centers, gene and cell therapy research institutions, and hematology hospitals, all of which are equipped to implement complex therapies such as CAR-T and gene therapy. For vaccines and conventional biopharmaceuticals, sales channels primarily rely on centralized government procurement, the medical insurance payment system, cold chain logistics, and commercial distribution. For example, domestic vaccines are distributed on a large scale through CDCs and vaccination sites, while blood products and monoclonal antibodies are distributed through hospital pharmacies, direct supply from pharmaceutical companies, and specialized distributors. With policy initiatives and evolving payment methods, volume-based procurement and medical insurance access have become key factors influencing the size of the downstream market. Furthermore, cold chain logistics (such as those provided by CIMC and Haier BioMedical) and third-party drug distribution (such as Jointown) play an indispensable role in ensuring transportation safety and efficiency. It can be said that the downstream sector is both the endpoint for biomanufacturing value realization and the core driver of market expansion and widespread adoption.

The upstream process for antibody drugs centers on cell culture and purification processes. Their production relies on key raw materials such as high-quality cell culture media, enzyme tools, and CHO cell lines. Furthermore, pipettes, chromatography media, and disposable consumables are crucial for process stability. Regarding equipment, large-scale stirred tanks and airlift tanks are the mainstream culture methods, coupled with separation and purification systems to ensure antibody product quality. In terms of supply, international manufacturers such as Thermo Fisher Scientific, Roche, and Illumina maintain their dominant position, while domestic companies such as LePure Biopharmaceuticals, Novozymes, and GenScript are gradually achieving breakthroughs in culture media, cell lines, and some consumables, driving import substitution.

The production process of recombinant protein drugs relies on genetically engineered vectors and host cell expression systems. The upstream process includes gene vector construction, cell culture, protein extraction, and chromatography purification. CHO cells remain the industry's mainstream host, and large-scale production is achieved through the integration of reactors, quality control instruments, and high-performance chromatography media. In the international market, giants such as Sartorius, Danaher (Cytiva), and GE Healthcare control high-end equipment and purification processes, while Chinese companies such as OptoMed, Sino Biological, and Labtech are gradually becoming competitive in some equipment and reagents. Overall, this sector demonstrates continued reliance on multinational companies, while domestic companies are rapidly catching up through technological accumulation.

The upstream process of blood products relies on the collection, separation, and purification of healthy human plasma, making apheresis centers the only legal source of raw materials. In terms of technology, traditional low-temperature ethanol separation processes are still widely used, but they lack purity and efficiency. Therefore, column chromatography and ultrafiltration technologies are gradually being introduced to improve protein yield and product safety. Upstream equipment includes plasma separation equipment, chromatography systems, and filtration consumables, with key suppliers primarily concentrated in the European and American markets. While domestic companies such as Hualan Biotechnology, Tiantan Biotechnology, and Shanghai RAAS have advantages in plasma collection and certain process technologies, they still rely on imports for high-end chromatography media and equipment.

The upstream component of vaccines is relatively complex, encompassing a variety of raw materials such as culture media, antibiotics, enzyme tools, liposomes, drug delivery vehicles, reagents, and packaging materials. At the equipment level, fermenters, reactors, separation and purification systems, and quality control instruments are essential core components. The global market is dominated by multinational giants such as Thermo Fisher Scientific, Danaher, and Sartorius, whose products are highly competitive in terms of quality and GMP standards. Chinese companies such as LePure Biotechnology, Novozymes, Dongfulong, Chutian Technology, and Jiankai Technology have gradually established scale in culture media, certain equipment, and purification consumables, demonstrating strong industrial responsiveness, particularly within the COVID-19 vaccine supply chain. The upstream process of CAR-T cell therapy relies on high-end equipment and key reagents. The production process relies on equipment such as flow cytometers, blood cell separation and elutriation machines, cell culture incubators, and biosafety cabinets. It also requires consumables such as magnetic bead enrichment columns, electroporators, and T-flasks, culture bags, and Wave reactors. Cytokines and transfection reagents are key ingredients for ensuring cell viability and the success rate of gene delivery. Currently, international companies such as GE Healthcare, Miltenyi, Lonza, and Thermo Fisher Scientific hold a commanding position in this field. While domestic companies offer some competitiveness in consumables pricing, their overall quality lags behind international standards, leading local R&D companies to rely more heavily on imported products.

The upstream process of small nucleic acid drugs primarily focuses on synthesis and purification. Core equipment includes solid-phase nucleic acid synthesizers and reversed-phase HPLC separation systems, combined with high-purity nucleotide monomers and reagents to complete the synthesis process. The international market is dominated by companies such as Cytiva (a Danaher subsidiary) and Thermo Fisher Scientific, which have established technological barriers to GMP-grade equipment and key consumables. In China, Nanotech, Lanxiao Technology, and Boglon are gradually replacing domestically produced materials in separation and purification fillers, driving down production costs. However, they still rely on imports for industrial synthesis equipment. As the industry scales up, breakthroughs in the domestic supply chain are seen as key to reducing costs and improving domestic controllability.

In recent years, the pharmaceutical industry's R&D focus has shifted from solely focusing on the discovery and optimization of small molecule drugs. Driven by biomanufacturing, the product portfolio has evolved into a multimodal, biology-centric landscape. While traditional proteins and monoclonal antibodies remain the bulk of the market, manufacturing processes are constantly being optimized to improve yield and quality consistency. Meanwhile, emerging therapeutic modalities such as cell and gene therapies, mRNA, nucleic acid therapies, and gene editing-related products are placing new demands on biomanufacturing. Upstream cell line development, expression system optimization, vector production, sterile and pyrogen-free downstream purification, and process stability for both in vitro and in vivo delivery systems have all become key R&D priorities. Consequently, the boundaries between R&D and manufacturing are becoming increasingly blurred: early-stage molecular design must consider manufacturability for scalable production, while process development, in turn, influences clinical dosing regimens and development cadence. With the maturity of AI/data-driven design, synthetic biology, and high-throughput screening technologies, the path from early target identification to producible biologics has been significantly shortened. This, in turn, requires manufacturing teams to engage earlier in early drug development to ensure that candidate molecules do not encounter unresolvable process bottlenecks when entering mid- to late-stage large-scale production. As a result, R&D trends are showing a significant shift from single-molecule innovation to molecule-process co-design. This trend will continue to intensify, driving companies to adjust their R&D organizational structures and investment allocations to balance scientific innovation with production feasibility.

The technological evolution of biomanufacturing is undergoing a transition from traditional batch processes to continuous production and intelligent manufacturing. Continuous bioreactors, real-time release testing (RTRT), online process analytical technology (PAT), and closed-loop automation systems can significantly improve unit capacity utilization, shorten release times, and reduce human errors, while also enabling rapid scale-up and flexible capacity adjustments. Digitalization (including production-level data platforms, AI-driven process optimization, and predictive maintenance) enables faster development of relationships between process parameters and quality attributes, accelerating improvements in batch yields. Regarding platformization, product lines such as monoclonal antibodies (mAbs) and viral vectors are increasingly adopting standardized platform processes: reusable expression systems, universal downstream purification columns, and modular facilities (such as mobile or "factory-as-a-module") to reduce the cost and time required to introduce new products. Green manufacturing and low-carbon processes are also gradually being incorporated into the technology pipeline, such as reducing solvent use and improving resource recycling. Overall, these technologies are characterized by high automation, strong data reliance, and platform-based reuse. This places higher demands on companies' R&D organizations, technical reserves, and capital investment, while also providing companies with advanced processes with a lasting competitive advantage.

The biomanufacturing sector is characterized by significant scale and technology concentration. Global large pharmaceutical companies and leading CDMOs/CMOs dominate high-end production capacity and complex process capabilities. At the same time, a large number of specialized small and medium-sized enterprises, contract research and production organizations, and technical service providers have emerged in the market, forming a complex network of collaborations. Large innovative pharmaceutical companies, driven by flexibility and cost considerations, are increasingly outsourcing some manufacturing to third-party CDMOs with scale and regulatory compliance, allowing them to focus their resources on core R&D and commercialization. In turn, CDMOs are rapidly increasing their bargaining power within the supply chain by investing in serialization, expanding sterile biologics production capacity, and acquiring key process patents through mergers and acquisitions. Furthermore, cross-border collaborations, licensing, co-development, and joint ventures are becoming common strategies for rapidly entering new markets or securing regional regulatory compliance pathways. It's worth noting that collaboration doesn't necessarily mean weakening competition: Building on platformization and standardization, companies are creating competitive barriers through differentiated services, patent portfolios, quality systems, and delivery capabilities. In short, the industry's key characteristics include a strong platform effect, a refined division of labor, and regularized collaboration. Within this ecosystem, there's both concentrated competition among large-scale companies and the rapid growth of small and medium-sized players relying on specialized capabilities.

This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Biomanufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Biomanufacturing.

The Pharmaceutical Biomanufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharmaceutical Biomanufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, by Class and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pharmaceutical Biomanufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Pharmaceutical Biomanufacturing Market Report

Report Metric	Details
Report Name	Pharmaceutical Biomanufacturing Market
Accounted market size in year	US$ 518560 million
Forecasted market size in 2031	US$ 951994 million
CAGR	9.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Antibody Drugs Recombinant Protein Drugs Blood Products Vaccine Preparations CAR-T Drugs Small Nucleic Acid Drugs Others
Segment by Class	Monoclonal Antibodies Antibody-drug Conjugates (ADCs) Peptide Drugs Enzyme Replacement Therapy Human Albumin Immunoglobulins Coagulation Factors COVID-19 Vaccines Other Vaccines CAR-T Drugs Small Nucleic Acid Drugs Others
Segment by Application	Oncology Infectious Diseases Immune and Inflammatory Diseases Endocrine and Metabolic Diseases Neurological Diseases Hematologic Diseases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Gilford, Biogen, GileadSciences, Moderna, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, Sobi, 3SBio Inc., Beijing Tiantan Biological, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Hualan Biological, Shanghai Henlius Biotech, Taibang Biologic, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology, Tonghua Dongbao Pharmaceutical, Shanghai Junshi Biosciences, Sichuan Yuanda Shuyang Pharmaceutical, Kexing Biopharm, Shanghai RAAS Blood Products, Chongqing Zhifei Biological Products, Beijing WANTAI Biological, Bio-Thera Solutions, Ionis Pharmaceuticals, Alphamab Oncology, CARsgen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Class etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical Biomanufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Pharmaceutical Biomanufacturing Market growing?

Ans: The Pharmaceutical Biomanufacturing Market witnessing a CAGR of 9.4% during the forecast period 2025-2031.

What is the Pharmaceutical Biomanufacturing Market size in 2031?

Ans: The Pharmaceutical Biomanufacturing Market size in 2031 will be US$ 951994 million.

Who are the main players in the Pharmaceutical Biomanufacturing Market report?

Ans: The main players in the Pharmaceutical Biomanufacturing Market are Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Gilford, Biogen, GileadSciences, Moderna, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, Sobi, 3SBio Inc., Beijing Tiantan Biological, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Hualan Biological, Shanghai Henlius Biotech, Taibang Biologic, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology, Tonghua Dongbao Pharmaceutical, Shanghai Junshi Biosciences, Sichuan Yuanda Shuyang Pharmaceutical, Kexing Biopharm, Shanghai RAAS Blood Products, Chongqing Zhifei Biological Products, Beijing WANTAI Biological, Bio-Thera Solutions, Ionis Pharmaceuticals, Alphamab Oncology, CARsgen

What are the Application segmentation covered in the Pharmaceutical Biomanufacturing Market report?

Ans: The Applications covered in the Pharmaceutical Biomanufacturing Market report are Oncology, Infectious Diseases, Immune and Inflammatory Diseases, Endocrine and Metabolic Diseases, Neurological Diseases, Hematologic Diseases, Others

What are the Type segmentation covered in the Pharmaceutical Biomanufacturing Market report?

Ans: The Types covered in the Pharmaceutical Biomanufacturing Market report are Antibody Drugs, Recombinant Protein Drugs, Blood Products, Vaccine Preparations, CAR-T Drugs, Small Nucleic Acid Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antibody Drugs

1.2.3 Recombinant Protein Drugs

1.2.4 Blood Products

1.2.5 Vaccine Preparations

1.2.6 CAR-T Drugs

1.2.7 Small Nucleic Acid Drugs

1.2.8 Others

1.3 Market by Class

1.3.1 Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Class: 2020 VS 2024 VS 2031

1.3.2 Monoclonal Antibodies

1.3.3 Antibody-drug Conjugates (ADCs)

1.3.4 Peptide Drugs

1.3.5 Enzyme Replacement Therapy

1.3.6 Human Albumin

1.3.7 Immunoglobulins

1.3.8 Coagulation Factors

1.3.9 COVID-19 Vaccines

1.3.10 Other Vaccines

1.4 Market by Application

1.4.1 Global Pharmaceutical Biomanufacturing Market Growth by Application: 2020 VS 2024 VS 2031

1.4.2 Oncology

1.4.3 Infectious Diseases

1.4.4 Immune and Inflammatory Diseases

1.4.5 Endocrine and Metabolic Diseases

1.4.6 Neurological Diseases

1.4.7 Hematologic Diseases

1.4.8 Others

1.5 Assumptions and Limitations

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Global Pharmaceutical Biomanufacturing Market Perspective (2020-2031)

2.2 Global Pharmaceutical Biomanufacturing Growth Trends by Region

2.2.1 Global Pharmaceutical Biomanufacturing Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Pharmaceutical Biomanufacturing Historic Market Size by Region (2020-2025)

2.2.3 Pharmaceutical Biomanufacturing Forecasted Market Size by Region (2026-2031)

2.3 Pharmaceutical Biomanufacturing Market Dynamics

2.3.1 Pharmaceutical Biomanufacturing Industry Trends

2.3.2 Pharmaceutical Biomanufacturing Market Drivers

2.3.3 Pharmaceutical Biomanufacturing Market Challenges

2.3.4 Pharmaceutical Biomanufacturing Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Pharmaceutical Biomanufacturing Players by Revenue

3.1.1 Global Top Pharmaceutical Biomanufacturing Players by Revenue (2020-2025)

3.1.2 Global Pharmaceutical Biomanufacturing Revenue Market Share by Players (2020-2025)

3.2 Global Top Pharmaceutical Biomanufacturing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Pharmaceutical Biomanufacturing Revenue

3.4 Global Pharmaceutical Biomanufacturing Market Concentration Ratio

3.4.1 Global Pharmaceutical Biomanufacturing Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical Biomanufacturing Revenue in 2024

3.5 Global Key Players of Pharmaceutical Biomanufacturing Head office and Area Served

3.6 Global Key Players of Pharmaceutical Biomanufacturing, Product and Application

3.7 Global Key Players of Pharmaceutical Biomanufacturing, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Pharmaceutical Biomanufacturing Breakdown Data by Type

4.1 Global Pharmaceutical Biomanufacturing Historic Market Size by Type (2020-2025)

4.2 Global Pharmaceutical Biomanufacturing Forecasted Market Size by Type (2026-2031)

5 Pharmaceutical Biomanufacturing Breakdown Data by Application

5.1 Global Pharmaceutical Biomanufacturing Historic Market Size by Application (2020-2025)

5.2 Global Pharmaceutical Biomanufacturing Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Pharmaceutical Biomanufacturing Market Size (2020-2031)

6.2 North America Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)

6.4 North America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Pharmaceutical Biomanufacturing Market Size (2020-2031)

7.2 Europe Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)

7.4 Europe Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Pharmaceutical Biomanufacturing Market Size (2020-2031)

8.2 Asia-Pacific Pharmaceutical Biomanufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2020-2025)

8.4 Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Pharmaceutical Biomanufacturing Market Size (2020-2031)

9.2 Latin America Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)

9.4 Latin America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Pharmaceutical Biomanufacturing Market Size (2020-2031)

10.2 Middle East & Africa Pharmaceutical Biomanufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2020-2025)

10.4 Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Pharmaceutical Biomanufacturing Introduction

11.1.4 Roche Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Merck

11.2.1 Merck Company Details

11.2.2 Merck Business Overview

11.2.3 Merck Pharmaceutical Biomanufacturing Introduction

11.2.4 Merck Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.2.5 Merck Recent Development

11.3 Novo Nordisk

11.3.1 Novo Nordisk Company Details

11.3.2 Novo Nordisk Business Overview

11.3.3 Novo Nordisk Pharmaceutical Biomanufacturing Introduction

11.3.4 Novo Nordisk Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.3.5 Novo Nordisk Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Details

11.4.2 Sanofi Business Overview

11.4.3 Sanofi Pharmaceutical Biomanufacturing Introduction

11.4.4 Sanofi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.4.5 Sanofi Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Pharmaceutical Biomanufacturing Introduction

11.5.4 Johnson & Johnson Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.5.5 Johnson & Johnson Recent Development

11.6 AbbVie

11.6.1 AbbVie Company Details

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Pharmaceutical Biomanufacturing Introduction

11.6.4 AbbVie Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.6.5 AbbVie Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Pharmaceutical Biomanufacturing Introduction

11.7.4 Amgen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Pharmaceutical Biomanufacturing Introduction

11.8.4 AstraZeneca Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Takeda Pharmaceuticals

11.9.1 Takeda Pharmaceuticals Company Details

11.9.2 Takeda Pharmaceuticals Business Overview

11.9.3 Takeda Pharmaceuticals Pharmaceutical Biomanufacturing Introduction

11.9.4 Takeda Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.9.5 Takeda Pharmaceuticals Recent Development

11.10 Bristol-Myers Squib

11.10.1 Bristol-Myers Squib Company Details

11.10.2 Bristol-Myers Squib Business Overview

11.10.3 Bristol-Myers Squib Pharmaceutical Biomanufacturing Introduction

11.10.4 Bristol-Myers Squib Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.10.5 Bristol-Myers Squib Recent Development

11.11 Pfizer

11.11.1 Pfizer Company Details

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Pharmaceutical Biomanufacturing Introduction

11.11.4 Pfizer Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.11.5 Pfizer Recent Development

11.12 Eli Lilly

11.12.1 Eli Lilly Company Details

11.12.2 Eli Lilly Business Overview

11.12.3 Eli Lilly Pharmaceutical Biomanufacturing Introduction

11.12.4 Eli Lilly Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.12.5 Eli Lilly Recent Development

11.13 Novartis

11.13.1 Novartis Company Details

11.13.2 Novartis Business Overview

11.13.3 Novartis Pharmaceutical Biomanufacturing Introduction

11.13.4 Novartis Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.13.5 Novartis Recent Development

11.14 GSK

11.14.1 GSK Company Details

11.14.2 GSK Business Overview

11.14.3 GSK Pharmaceutical Biomanufacturing Introduction

11.14.4 GSK Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.14.5 GSK Recent Development

11.15 CSL Limited

11.15.1 CSL Limited Company Details

11.15.2 CSL Limited Business Overview

11.15.3 CSL Limited Pharmaceutical Biomanufacturing Introduction

11.15.4 CSL Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.15.5 CSL Limited Recent Development

11.16 Regeneron Pharmaceuticals

11.16.1 Regeneron Pharmaceuticals Company Details

11.16.2 Regeneron Pharmaceuticals Business Overview

11.16.3 Regeneron Pharmaceuticals Pharmaceutical Biomanufacturing Introduction

11.16.4 Regeneron Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.16.5 Regeneron Pharmaceuticals Recent Development

11.17 Gilford

11.17.1 Gilford Company Details

11.17.2 Gilford Business Overview

11.17.3 Gilford Pharmaceutical Biomanufacturing Introduction

11.17.4 Gilford Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.17.5 Gilford Recent Development

11.18 Biogen

11.18.1 Biogen Company Details

11.18.2 Biogen Business Overview

11.18.3 Biogen Pharmaceutical Biomanufacturing Introduction

11.18.4 Biogen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.18.5 Biogen Recent Development

11.19 GileadSciences

11.19.1 GileadSciences Company Details

11.19.2 GileadSciences Business Overview

11.19.3 GileadSciences Pharmaceutical Biomanufacturing Introduction

11.19.4 GileadSciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.19.5 GileadSciences Recent Development

11.20 Moderna

11.20.1 Moderna Company Details

11.20.2 Moderna Business Overview

11.20.3 Moderna Pharmaceutical Biomanufacturing Introduction

11.20.4 Moderna Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.20.5 Moderna Recent Development

11.21 Sarepta Therapeutics, Inc.

11.21.1 Sarepta Therapeutics, Inc. Company Details

11.21.2 Sarepta Therapeutics, Inc. Business Overview

11.21.3 Sarepta Therapeutics, Inc. Pharmaceutical Biomanufacturing Introduction

11.21.4 Sarepta Therapeutics, Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.21.5 Sarepta Therapeutics, Inc. Recent Development

11.22 Changchun High-Tech Industry

11.22.1 Changchun High-Tech Industry Company Details

11.22.2 Changchun High-Tech Industry Business Overview

11.22.3 Changchun High-Tech Industry Pharmaceutical Biomanufacturing Introduction

11.22.4 Changchun High-Tech Industry Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.22.5 Changchun High-Tech Industry Recent Development

11.23 Sino Biopharmaceutical Limited

11.23.1 Sino Biopharmaceutical Limited Company Details

11.23.2 Sino Biopharmaceutical Limited Business Overview

11.23.3 Sino Biopharmaceutical Limited Pharmaceutical Biomanufacturing Introduction

11.23.4 Sino Biopharmaceutical Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.23.5 Sino Biopharmaceutical Limited Recent Development

11.24 Sobi

11.24.1 Sobi Company Details

11.24.2 Sobi Business Overview

11.24.3 Sobi Pharmaceutical Biomanufacturing Introduction

11.24.4 Sobi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.24.5 Sobi Recent Development

11.25 3SBio Inc.

11.25.1 3SBio Inc. Company Details

11.25.2 3SBio Inc. Business Overview

11.25.3 3SBio Inc. Pharmaceutical Biomanufacturing Introduction

11.25.4 3SBio Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.25.5 3SBio Inc. Recent Development

11.26 Beijing Tiantan Biological

11.26.1 Beijing Tiantan Biological Company Details

11.26.2 Beijing Tiantan Biological Business Overview

11.26.3 Beijing Tiantan Biological Pharmaceutical Biomanufacturing Introduction

11.26.4 Beijing Tiantan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.26.5 Beijing Tiantan Biological Recent Development

11.27 Innovent Biologics

11.27.1 Innovent Biologics Company Details

11.27.2 Innovent Biologics Business Overview

11.27.3 Innovent Biologics Pharmaceutical Biomanufacturing Introduction

11.27.4 Innovent Biologics Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.27.5 Innovent Biologics Recent Development

11.28 Qilu Pharmaceutical

11.28.1 Qilu Pharmaceutical Company Details

11.28.2 Qilu Pharmaceutical Business Overview

11.28.3 Qilu Pharmaceutical Pharmaceutical Biomanufacturing Introduction

11.28.4 Qilu Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.28.5 Qilu Pharmaceutical Recent Development

11.29 Boehringer Ingelheim

11.29.1 Boehringer Ingelheim Company Details

11.29.2 Boehringer Ingelheim Business Overview

11.29.3 Boehringer Ingelheim Pharmaceutical Biomanufacturing Introduction

11.29.4 Boehringer Ingelheim Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.29.5 Boehringer Ingelheim Recent Development

11.30 BeiGene

11.30.1 BeiGene Company Details

11.30.2 BeiGene Business Overview

11.30.3 BeiGene Pharmaceutical Biomanufacturing Introduction

11.30.4 BeiGene Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.30.5 BeiGene Recent Development

11.31 Jiangsu Hengrui Pharmaceuticals

11.31.1 Jiangsu Hengrui Pharmaceuticals Company Details

11.31.2 Jiangsu Hengrui Pharmaceuticals Business Overview

11.31.3 Jiangsu Hengrui Pharmaceuticals Pharmaceutical Biomanufacturing Introduction

11.31.4 Jiangsu Hengrui Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.31.5 Jiangsu Hengrui Pharmaceuticals Recent Development

11.32 Hualan Biological

11.32.1 Hualan Biological Company Details

11.32.2 Hualan Biological Business Overview

11.32.3 Hualan Biological Pharmaceutical Biomanufacturing Introduction

11.32.4 Hualan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.32.5 Hualan Biological Recent Development

11.33 Shanghai Henlius Biotech

11.33.1 Shanghai Henlius Biotech Company Details

11.33.2 Shanghai Henlius Biotech Business Overview

11.33.3 Shanghai Henlius Biotech Pharmaceutical Biomanufacturing Introduction

11.33.4 Shanghai Henlius Biotech Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.33.5 Shanghai Henlius Biotech Recent Development

11.34 Taibang Biologic

11.34.1 Taibang Biologic Company Details

11.34.2 Taibang Biologic Business Overview

11.34.3 Taibang Biologic Pharmaceutical Biomanufacturing Introduction

11.34.4 Taibang Biologic Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.34.5 Taibang Biologic Recent Development

11.35 Gan & Lee Pharmaceuticals

11.35.1 Gan & Lee Pharmaceuticals Company Details

11.35.2 Gan & Lee Pharmaceuticals Business Overview

11.35.3 Gan & Lee Pharmaceuticals Pharmaceutical Biomanufacturing Introduction

11.35.4 Gan & Lee Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.35.5 Gan & Lee Pharmaceuticals Recent Development

11.36 Anhui Anke Biotechnology

11.36.1 Anhui Anke Biotechnology Company Details

11.36.2 Anhui Anke Biotechnology Business Overview

11.36.3 Anhui Anke Biotechnology Pharmaceutical Biomanufacturing Introduction

11.36.4 Anhui Anke Biotechnology Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.36.5 Anhui Anke Biotechnology Recent Development

11.37 Tonghua Dongbao Pharmaceutical

11.37.1 Tonghua Dongbao Pharmaceutical Company Details

11.37.2 Tonghua Dongbao Pharmaceutical Business Overview

11.37.3 Tonghua Dongbao Pharmaceutical Pharmaceutical Biomanufacturing Introduction

11.37.4 Tonghua Dongbao Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.37.5 Tonghua Dongbao Pharmaceutical Recent Development

11.38 Shanghai Junshi Biosciences

11.38.1 Shanghai Junshi Biosciences Company Details

11.38.2 Shanghai Junshi Biosciences Business Overview

11.38.3 Shanghai Junshi Biosciences Pharmaceutical Biomanufacturing Introduction

11.38.4 Shanghai Junshi Biosciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.38.5 Shanghai Junshi Biosciences Recent Development

11.39 Sichuan Yuanda Shuyang Pharmaceutical

11.39.1 Sichuan Yuanda Shuyang Pharmaceutical Company Details

11.39.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview

11.39.3 Sichuan Yuanda Shuyang Pharmaceutical Pharmaceutical Biomanufacturing Introduction

11.39.4 Sichuan Yuanda Shuyang Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.39.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Development

11.40 Kexing Biopharm

11.40.1 Kexing Biopharm Company Details

11.40.2 Kexing Biopharm Business Overview

11.40.3 Kexing Biopharm Pharmaceutical Biomanufacturing Introduction

11.40.4 Kexing Biopharm Revenue in Pharmaceutical Biomanufacturing Business (2020-2025)

11.40.5 Kexing Biopharm Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antibody Drugs

Table 3. Key Players of Recombinant Protein Drugs

Table 4. Key Players of Blood Products

Table 5. Key Players of Vaccine Preparations

Table 6. Key Players of CAR-T Drugs

Table 7. Key Players of Small Nucleic Acid Drugs

Table 8. Key Players of Others

Table 9. Global Pharmaceutical Biomanufacturing Market Size Growth Rate by Class (US$ Million): 2020 VS 2024 VS 2031

Table 10. Key Players of Monoclonal Antibodies

Table 11. Key Players of Antibody-drug Conjugates (ADCs)

Table 12. Key Players of Peptide Drugs

Table 13. Key Players of Enzyme Replacement Therapy

Table 14. Key Players of Human Albumin

Table 15. Key Players of Immunoglobulins

Table 16. Key Players of Coagulation Factors

Table 17. Global Pharmaceutical Biomanufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 18. Global Pharmaceutical Biomanufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global Pharmaceutical Biomanufacturing Market Size by Region (2020-2025) & (US$ Million)

Table 20. Global Pharmaceutical Biomanufacturing Market Share by Region (2020-2025)

Table 21. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 22. Global Pharmaceutical Biomanufacturing Market Share by Region (2026-2031)

Table 23. Pharmaceutical Biomanufacturing Market Trends

Table 24. Pharmaceutical Biomanufacturing Market Drivers

Table 25. Pharmaceutical Biomanufacturing Market Challenges

Table 26. Pharmaceutical Biomanufacturing Market Restraints

Table 27. Global Pharmaceutical Biomanufacturing Revenue by Players (2020-2025) & (US$ Million)

Table 28. Global Pharmaceutical Biomanufacturing Market Share by Players (2020-2025)

Table 29. Global Top Pharmaceutical Biomanufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Biomanufacturing as of 2024)

Table 30. Ranking of Global Top Pharmaceutical Biomanufacturing Companies by Revenue (US$ Million) in 2024

Table 31. Global 5 Largest Players Market Share by Pharmaceutical Biomanufacturing Revenue (CR5 and HHI) & (2020-2025)

Table 32. Global Key Players of Pharmaceutical Biomanufacturing, Headquarters and Area Served

Table 33. Global Key Players of Pharmaceutical Biomanufacturing, Product and Application

Table 34. Global Key Players of Pharmaceutical Biomanufacturing, Date of Enter into This Industry

Table 35. Mergers & Acquisitions, Expansion Plans

Table 36. Global Pharmaceutical Biomanufacturing Market Size by Type (2020-2025) & (US$ Million)

Table 37. Global Pharmaceutical Biomanufacturing Revenue Market Share by Type (2020-2025)

Table 38. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 39. Global Pharmaceutical Biomanufacturing Revenue Market Share by Type (2026-2031)

Table 40. Global Pharmaceutical Biomanufacturing Market Size by Application (2020-2025) & (US$ Million)

Table 41. Global Pharmaceutical Biomanufacturing Revenue Market Share by Application (2020-2025)

Table 42. Global Pharmaceutical Biomanufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 43. Global Pharmaceutical Biomanufacturing Revenue Market Share by Application (2026-2031)

Table 44. North America Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. North America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)

Table 46. North America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)

Table 47. Europe Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Europe Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)

Table 49. Europe Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)

Table 50. Asia-Pacific Pharmaceutical Biomanufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 51. Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2020-2025) & (US$ Million)

Table 52. Asia-Pacific Pharmaceutical Biomanufacturing Market Size by Region (2026-2031) & (US$ Million)

Table 53. Latin America Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 54. Latin America Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)

Table 55. Latin America Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)

Table 56. Middle East & Africa Pharmaceutical Biomanufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 57. Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2020-2025) & (US$ Million)

Table 58. Middle East & Africa Pharmaceutical Biomanufacturing Market Size by Country (2026-2031) & (US$ Million)

Table 59. Roche Company Details

Table 60. Roche Business Overview

Table 61. Roche Pharmaceutical Biomanufacturing Product

Table 62. Roche Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 63. Roche Recent Development

Table 64. Merck Company Details

Table 65. Merck Business Overview

Table 66. Merck Pharmaceutical Biomanufacturing Product

Table 67. Merck Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 68. Merck Recent Development

Table 69. Novo Nordisk Company Details

Table 70. Novo Nordisk Business Overview

Table 71. Novo Nordisk Pharmaceutical Biomanufacturing Product

Table 72. Novo Nordisk Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 73. Novo Nordisk Recent Development

Table 74. Sanofi Company Details

Table 75. Sanofi Business Overview

Table 76. Sanofi Pharmaceutical Biomanufacturing Product

Table 77. Sanofi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 78. Sanofi Recent Development

Table 79. Johnson & Johnson Company Details

Table 80. Johnson & Johnson Business Overview

Table 81. Johnson & Johnson Pharmaceutical Biomanufacturing Product

Table 82. Johnson & Johnson Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 83. Johnson & Johnson Recent Development

Table 84. AbbVie Company Details

Table 85. AbbVie Business Overview

Table 86. AbbVie Pharmaceutical Biomanufacturing Product

Table 87. AbbVie Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 88. AbbVie Recent Development

Table 89. Amgen Company Details

Table 90. Amgen Business Overview

Table 91. Amgen Pharmaceutical Biomanufacturing Product

Table 92. Amgen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 93. Amgen Recent Development

Table 94. AstraZeneca Company Details

Table 95. AstraZeneca Business Overview

Table 96. AstraZeneca Pharmaceutical Biomanufacturing Product

Table 97. AstraZeneca Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 98. AstraZeneca Recent Development

Table 99. Takeda Pharmaceuticals Company Details

Table 100. Takeda Pharmaceuticals Business Overview

Table 101. Takeda Pharmaceuticals Pharmaceutical Biomanufacturing Product

Table 102. Takeda Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 103. Takeda Pharmaceuticals Recent Development

Table 104. Bristol-Myers Squib Company Details

Table 105. Bristol-Myers Squib Business Overview

Table 106. Bristol-Myers Squib Pharmaceutical Biomanufacturing Product

Table 107. Bristol-Myers Squib Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 108. Bristol-Myers Squib Recent Development

Table 109. Pfizer Company Details

Table 110. Pfizer Business Overview

Table 111. Pfizer Pharmaceutical Biomanufacturing Product

Table 112. Pfizer Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 113. Pfizer Recent Development

Table 114. Eli Lilly Company Details

Table 115. Eli Lilly Business Overview

Table 116. Eli Lilly Pharmaceutical Biomanufacturing Product

Table 117. Eli Lilly Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 118. Eli Lilly Recent Development

Table 119. Novartis Company Details

Table 120. Novartis Business Overview

Table 121. Novartis Pharmaceutical Biomanufacturing Product

Table 122. Novartis Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 123. Novartis Recent Development

Table 124. GSK Company Details

Table 125. GSK Business Overview

Table 126. GSK Pharmaceutical Biomanufacturing Product

Table 127. GSK Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 128. GSK Recent Development

Table 129. CSL Limited Company Details

Table 130. CSL Limited Business Overview

Table 131. CSL Limited Pharmaceutical Biomanufacturing Product

Table 132. CSL Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 133. CSL Limited Recent Development

Table 134. Regeneron Pharmaceuticals Company Details

Table 135. Regeneron Pharmaceuticals Business Overview

Table 136. Regeneron Pharmaceuticals Pharmaceutical Biomanufacturing Product

Table 137. Regeneron Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 138. Regeneron Pharmaceuticals Recent Development

Table 139. Gilford Company Details

Table 140. Gilford Business Overview

Table 141. Gilford Pharmaceutical Biomanufacturing Product

Table 142. Gilford Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 143. Gilford Recent Development

Table 144. Biogen Company Details

Table 145. Biogen Business Overview

Table 146. Biogen Pharmaceutical Biomanufacturing Product

Table 147. Biogen Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 148. Biogen Recent Development

Table 149. GileadSciences Company Details

Table 150. GileadSciences Business Overview

Table 151. GileadSciences Pharmaceutical Biomanufacturing Product

Table 152. GileadSciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 153. GileadSciences Recent Development

Table 154. Moderna Company Details

Table 155. Moderna Business Overview

Table 156. Moderna Pharmaceutical Biomanufacturing Product

Table 157. Moderna Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 158. Moderna Recent Development

Table 159. Sarepta Therapeutics, Inc. Company Details

Table 160. Sarepta Therapeutics, Inc. Business Overview

Table 161. Sarepta Therapeutics, Inc. Pharmaceutical Biomanufacturing Product

Table 162. Sarepta Therapeutics, Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 163. Sarepta Therapeutics, Inc. Recent Development

Table 164. Changchun High-Tech Industry Company Details

Table 165. Changchun High-Tech Industry Business Overview

Table 166. Changchun High-Tech Industry Pharmaceutical Biomanufacturing Product

Table 167. Changchun High-Tech Industry Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 168. Changchun High-Tech Industry Recent Development

Table 169. Sino Biopharmaceutical Limited Company Details

Table 170. Sino Biopharmaceutical Limited Business Overview

Table 171. Sino Biopharmaceutical Limited Pharmaceutical Biomanufacturing Product

Table 172. Sino Biopharmaceutical Limited Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 173. Sino Biopharmaceutical Limited Recent Development

Table 174. Sobi Company Details

Table 175. Sobi Business Overview

Table 176. Sobi Pharmaceutical Biomanufacturing Product

Table 177. Sobi Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 178. Sobi Recent Development

Table 179. 3SBio Inc. Company Details

Table 180. 3SBio Inc. Business Overview

Table 181. 3SBio Inc. Pharmaceutical Biomanufacturing Product

Table 182. 3SBio Inc. Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 183. 3SBio Inc. Recent Development

Table 184. Beijing Tiantan Biological Company Details

Table 185. Beijing Tiantan Biological Business Overview

Table 186. Beijing Tiantan Biological Pharmaceutical Biomanufacturing Product

Table 187. Beijing Tiantan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 188. Beijing Tiantan Biological Recent Development

Table 189. Innovent Biologics Company Details

Table 190. Innovent Biologics Business Overview

Table 191. Innovent Biologics Pharmaceutical Biomanufacturing Product

Table 192. Innovent Biologics Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 193. Innovent Biologics Recent Development

Table 194. Qilu Pharmaceutical Company Details

Table 195. Qilu Pharmaceutical Business Overview

Table 196. Qilu Pharmaceutical Pharmaceutical Biomanufacturing Product

Table 197. Qilu Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 198. Qilu Pharmaceutical Recent Development

Table 199. Boehringer Ingelheim Company Details

Table 200. Boehringer Ingelheim Business Overview

Table 201. Boehringer Ingelheim Pharmaceutical Biomanufacturing Product

Table 202. Boehringer Ingelheim Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 203. Boehringer Ingelheim Recent Development

Table 204. BeiGene Company Details

Table 205. BeiGene Business Overview

Table 206. BeiGene Pharmaceutical Biomanufacturing Product

Table 207. BeiGene Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 208. BeiGene Recent Development

Table 209. Jiangsu Hengrui Pharmaceuticals Company Details

Table 210. Jiangsu Hengrui Pharmaceuticals Business Overview

Table 211. Jiangsu Hengrui Pharmaceuticals Pharmaceutical Biomanufacturing Product

Table 212. Jiangsu Hengrui Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 213. Jiangsu Hengrui Pharmaceuticals Recent Development

Table 214. Hualan Biological Company Details

Table 215. Hualan Biological Business Overview

Table 216. Hualan Biological Pharmaceutical Biomanufacturing Product

Table 217. Hualan Biological Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 218. Hualan Biological Recent Development

Table 219. Shanghai Henlius Biotech Company Details

Table 220. Shanghai Henlius Biotech Business Overview

Table 221. Shanghai Henlius Biotech Pharmaceutical Biomanufacturing Product

Table 222. Shanghai Henlius Biotech Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 223. Shanghai Henlius Biotech Recent Development

Table 224. Taibang Biologic Company Details

Table 225. Taibang Biologic Business Overview

Table 226. Taibang Biologic Pharmaceutical Biomanufacturing Product

Table 227. Taibang Biologic Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 228. Taibang Biologic Recent Development

Table 229. Gan & Lee Pharmaceuticals Company Details

Table 230. Gan & Lee Pharmaceuticals Business Overview

Table 231. Gan & Lee Pharmaceuticals Pharmaceutical Biomanufacturing Product

Table 232. Gan & Lee Pharmaceuticals Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 233. Gan & Lee Pharmaceuticals Recent Development

Table 234. Anhui Anke Biotechnology Company Details

Table 235. Anhui Anke Biotechnology Business Overview

Table 236. Anhui Anke Biotechnology Pharmaceutical Biomanufacturing Product

Table 237. Anhui Anke Biotechnology Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 238. Anhui Anke Biotechnology Recent Development

Table 239. Tonghua Dongbao Pharmaceutical Company Details

Table 240. Tonghua Dongbao Pharmaceutical Business Overview

Table 241. Tonghua Dongbao Pharmaceutical Pharmaceutical Biomanufacturing Product

Table 242. Tonghua Dongbao Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 243. Tonghua Dongbao Pharmaceutical Recent Development

Table 244. Shanghai Junshi Biosciences Company Details

Table 245. Shanghai Junshi Biosciences Business Overview

Table 246. Shanghai Junshi Biosciences Pharmaceutical Biomanufacturing Product

Table 247. Shanghai Junshi Biosciences Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 248. Shanghai Junshi Biosciences Recent Development

Table 249. Sichuan Yuanda Shuyang Pharmaceutical Company Details

Table 250. Sichuan Yuanda Shuyang Pharmaceutical Business Overview

Table 251. Sichuan Yuanda Shuyang Pharmaceutical Pharmaceutical Biomanufacturing Product

Table 252. Sichuan Yuanda Shuyang Pharmaceutical Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 253. Sichuan Yuanda Shuyang Pharmaceutical Recent Development

Table 254. Kexing Biopharm Company Details

Table 255. Kexing Biopharm Business Overview

Table 256. Kexing Biopharm Pharmaceutical Biomanufacturing Product

Table 257. Kexing Biopharm Revenue in Pharmaceutical Biomanufacturing Business (2020-2025) & (US$ Million)

Table 258. Kexing Biopharm Recent Development

Table 259. Research Programs/Design for This Report

Table 260. Key Data Information from Secondary Sources

Table 261. Key Data Information from Primary Sources

Table 262. Authors List of This Report

List of Figures

Figure 1. Pharmaceutical Biomanufacturing Picture

Figure 2. Global Pharmaceutical Biomanufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Pharmaceutical Biomanufacturing Market Share by Type: 2024 VS 2031

Figure 4. Antibody Drugs Features

Figure 5. Recombinant Protein Drugs Features

Figure 6. Blood Products Features

Figure 7. Vaccine Preparations Features

Figure 8. CAR-T Drugs Features

Figure 9. Small Nucleic Acid Drugs Features

Figure 10. Others Features

Figure 11. Global Pharmaceutical Biomanufacturing Market Size Comparison by Class (2020-2031) & (US$ Million)

Figure 12. Monoclonal Antibodies Features

Figure 13. Antibody-drug Conjugates (ADCs) Features

Figure 14. Peptide Drugs Features

Figure 15. Enzyme Replacement Therapy Features

Figure 16. Human Albumin Features

Figure 17. Immunoglobulins Features

Figure 18. Coagulation Factors Features

Figure 19. COVID-19 Vaccines Features

Figure 20. Other Vaccines Features

Figure 21. Global Pharmaceutical Biomanufacturing Market Size by Application (2020-2031) & (US$ Million)

Figure 22. Global Pharmaceutical Biomanufacturing Market Share by Application: 2024 VS 2031

Figure 23. Oncology Case Studies

Figure 24. Infectious Diseases Case Studies

Figure 25. Immune and Inflammatory Diseases Case Studies

Figure 26. Endocrine and Metabolic Diseases Case Studies

Figure 27. Neurological Diseases Case Studies

Figure 28. Hematologic Diseases Case Studies

Figure 29. Others Case Studies

Figure 30. Pharmaceutical Biomanufacturing Report Years Considered

Figure 31. Global Pharmaceutical Biomanufacturing Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 32. Global Pharmaceutical Biomanufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 33. Global Pharmaceutical Biomanufacturing Market Share by Region: 2024 VS 2031

Figure 34. Global Pharmaceutical Biomanufacturing Market Share by Players in 2024

Figure 35. Global Pharmaceutical Biomanufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 36. The Top 10 and 5 Players Market Share by Pharmaceutical Biomanufacturing Revenue in 2024

Figure 37. North America Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. North America Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)

Figure 39. United States Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Canada Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Europe Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Europe Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)

Figure 43. Germany Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. France Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. U.K. Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Italy Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Russia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Ireland Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Asia-Pacific Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Pharmaceutical Biomanufacturing Market Share by Region (2020-2031)

Figure 51. China Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Japan Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. South Korea Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Southeast Asia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. India Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Australia & New Zealand Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. Latin America Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 58. Latin America Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)

Figure 59. Mexico Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 60. Brazil Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 61. Middle East & Africa Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 62. Middle East & Africa Pharmaceutical Biomanufacturing Market Share by Country (2020-2031)

Figure 63. Israel Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 64. Saudi Arabia Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 65. UAE Pharmaceutical Biomanufacturing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 66. Roche Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 67. Merck Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 68. Novo Nordisk Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 69. Sanofi Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 70. Johnson & Johnson Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 71. AbbVie Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 72. Amgen Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 73. AstraZeneca Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 74. Takeda Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 75. Bristol-Myers Squib Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 76. Pfizer Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 77. Eli Lilly Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 78. Novartis Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 79. GSK Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 80. CSL Limited Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 81. Regeneron Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 82. Gilford Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 83. Biogen Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 84. GileadSciences Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 85. Moderna Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 86. Sarepta Therapeutics, Inc. Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 87. Changchun High-Tech Industry Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 88. Sino Biopharmaceutical Limited Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 89. Sobi Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 90. 3SBio Inc. Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 91. Beijing Tiantan Biological Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 92. Innovent Biologics Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 93. Qilu Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 94. Boehringer Ingelheim Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 95. BeiGene Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 96. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 97. Hualan Biological Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 98. Shanghai Henlius Biotech Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 99. Taibang Biologic Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 100. Gan & Lee Pharmaceuticals Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 101. Anhui Anke Biotechnology Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 102. Tonghua Dongbao Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 103. Shanghai Junshi Biosciences Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 104. Sichuan Yuanda Shuyang Pharmaceutical Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 105. Kexing Biopharm Revenue Growth Rate in Pharmaceutical Biomanufacturing Business (2020-2025)

Figure 106. Bottom-up and Top-down Approaches for This Report

Figure 107. Data Triangulation

Figure 108. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global PAC Automatic Dosing Device Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8S20198

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Optically Clear PCR Strip Tubes Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-1L20132

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Avena Sativa Kernel Meal Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28Q19902

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Pharmaceutical Biomanufacturing Market Research Report 2025

Published Date: December 2025

Report Code: QYRE-Auto-26E19785

Global Pharmaceutical Biomanufacturing Market Research Report 2025

FEATURED COMPANIES

Pharmaceutical Biomanufacturing Market Size

Pharmaceutical Biomanufacturing Market

Scope of Pharmaceutical Biomanufacturing Market Report

Chapter Outline

FAQ for this report

How fast is Pharmaceutical Biomanufacturing Market growing?

What is the Pharmaceutical Biomanufacturing Market size in 2031?

Who are the main players in the Pharmaceutical Biomanufacturing Market report?

What are the Application segmentation covered in the Pharmaceutical Biomanufacturing Market report?

What are the Type segmentation covered in the Pharmaceutical Biomanufacturing Market report?

FEATURED COMPANIES

RELATED REPORTS